Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R., Munro, Trent P.
Published in EBioMedicine (01.11.2023)
Published in EBioMedicine (01.11.2023)
Get full text
Journal Article
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context
Keith J. Chappell, Francesca L. Mordant, Alberto A. Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Danushka K. Wijesundara, Julia A. Lackenby, Paul Griffin, Jillian K. Bennet, Luca Hensen, Wuji Zhang, Thi H.O. Nguyen, Mai H. Tran, Peter Tapley, James Barnes, Patrick C. Reading, Katherine Kedzierska, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro
Published in EBioMedicine (01.11.2023)
Get full text
Published in EBioMedicine (01.11.2023)
Journal Article